Repligen opened lower at $177.44, compared with its previous close of $188.64. In the last trading session, the stock traded between $171.23 and $180.45. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Repligen is now worth
$ 60.07
resulting in a loss of
$ 39.93 (39.93%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 8 Analysts
Buy
87.5%
Hold
12.5%
Sell
0%
Markets Today
Today's Change
$-14.12 (-7.49%)
Day High
$180.45
Day Low
$171.23
Day Open
$177.44
Prev Close
$188.64
Volume
27,20,713
1W Return
-2.29%
1M Return
-10.36%
3M Return
23.48%
6M Return
54.29%
1Y Return
17.54%
Fundamentals
Market Cap ($ Mn)
11,080
PE Ratio
241.42
PB Ratio
4.71
PEG Ratio
-
ROE
2.39%
ROCE
3.04%
EPS (TTM)
$0.09
Investment Returns
1 Week
-2.29%
1 Month
-10.36%
3 Months
23.48%
6 Months
54.29%
9 Months
11.60%
Financials
Quarterly
All values in $ Mn
169.2
Mar 25
182.4
Jun 25
188.8
Sep 25
197.9
Dec 25
194.3
Mar 26
204.1
Jun 26
Updates
26Aug
Repligen to present at Wells Fargo Healthcare Conference
Repligen Corporation (NASDAQ: RGEN) to present at Wells Fargo Healthcare Conference. CEO Olivier Loeillot and CFO Jason Garland to join analyst-led discussion. Presentation scheduled for September 9 at 1:30 p.m. ET in Boston. Live webcast available via company Investor Relations website.
2mo ago
28Jul
Repligen raises FY2026 adj EPS guidance to $2.03-$2.09
Repligen raises FY2026 adjusted EPS guidance to $2.03-$2.09, beating the $2.00 estimate. Sales outlook is also upgraded to $813.000M-$835.000M, surpassing the $822.537M consensus. The revisions reflect strong operational momentum and robust demand across the bioprocessing sector.
3mo ago
22Jul
Repligen to acquire BioLife for $31 per share in $1.5B deal
Repligen Corporation has agreed to acquire BioLife Solutions for approximately $1.5 billion, paying $31.00 per share. The deal is expected to be accretive to earnings by at least 5 cents in year one.
3mo ago
15Jul
Repligen to report Q2 2026 financial results on July 28
Repligen Corporation will announce its Q2 2026 financial results on July 28, 2026, followed by a conference call at 8:00 a.m. ET. The results will cover the period ended June 30, 2026.
3mo ago
7Jul
Benchmark upgrades Repligen to Buy, sets $185 target
Benchmark analyst Robert Wasserman upgraded Repligen from Hold to Buy and set a price target of $185.
3mo ago
7Jul
Evercore ISI raises Repligen price target to $160
Evercore ISI Group analyst Daniel Markowitz maintained an Outperform rating on Repligen (NASDAQ: RGEN) and raised the price target to $160 from $150.
